Piperacillin/Tazobactam: Piperacillin/tazobactam: 4.5g IV q6h (over 3h)
Piperacillin/tazobactam + Levofloxacin: Piperacillin/tazobactam: 4.5g IV q6h (over 3h)
\+ Levofloxacin 750mg IV q24h (over 30min)
Study summary
This study aims to provide high-level evidence for appropriate empirical antibiotic use tailored to the clinical reality in Korea by conducting a randomized controlled trial comparing monotherapy with piperacillin/tazobactam and combination therapy with piperacillin/tazobactam plus a fluoroquinolone in patients with severe community-acquired pneumonia.
Eligibility
Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
* Inclusion Criteria:
* Adult patients aged 19 years or older who visited the emergency department and were hospitalized.
* Findings consistent with pneumonia diagnosis, meeting all of the following criteria:
* Radiologic evidence of pulmonary infiltration on chest X-ray or chest CT.
* At least two or more of the following clinical signs:
i) Body temperature ≥38°C or \<36°C ii) White blood cell count ≥11,000/µL or \<4,000/µL iii) Presence of purulent sputum or bronchial secretions
* Within 24 hours of admission, the patient meets one major criterion or three minor criteria according to ATS/IDSA classification:
* Major criteria:
i) Invasive mechanical ventilation ii) Use of vasopressors (vasopressor-dependent septic shock)
* Minor criteria:
i) Respiratory rate ≥30 breaths/min ii) PaO2/FiO2 ≤ 250 iii) Multilobar infiltrates iv) Confusion or disorientation v) BUN ≥20 mg/dL vi) WBC \<4,000/mm³ vii) Platelet count \<100,000/mm³ viii) Hypothermia (temperature \<36°C) ix) Hypotension requiring aggressive fluid resuscitation
* Exclusion Criteria:
* Transferred from another hospital after \>48 hours of hospitalization
* Died within 72 hours of hospital admission
* Transferred to another hospital within 14 days of admission
* Pneumonia occurring after \>48 hours of mechanical ventilation, including home ventilators
* Detection of influenza or SARS-CoV-2 virus within 7 days of hospitalization
* Identified non-pneumonia infection requiring antibiotics within 72 hours of admission
* Detection of piperacillin/tazobactam-resistant Enterobacterales, Pseudomonas spp., or Acinetobacter spp. in respiratory or blood cultures within the past 90 days
* Antibiotic-related adverse events observed within 72 hours of assigned treatment, requiring discontinuation or change of antibiotics
Primary outcome measure(s)
All-cause 28-day mortality — 28 days Mortality from any cause within 28 days of randomization.
Trial sites (1)
Facility
City
Region
Status
Hanyang University Seoul Hospital
Seoul
Seoul
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.